1. Introduction {#s1}
===============

Thrombosis and hemorrhage represent the main challenges of myocardial revascularization.[@b1],[@b2] Platelets play a key role in the pathophysiological process of both thrombosis and hemorrhage.[@b3],[@b4] An abnormal increase (thrombocytosis) or decrease (thrombocytopenia) in platelets may cause defective formation of hemostatic plugs and bleeding.[@b5],[@b6] Accordingly, such patients were excluded from the vast majority of clinical trials, given the potentially increased risks. Few pooled post-hoc analyses[@b7]--[@b15] and cohort studies[@b13]--[@b15] drew inconsistent conclusions based on data mostly from thrombolysis or bare metal stents (BMS) era. Furthermore, contemporary treatment regimens have changed a lot over the last decade with common use of drug eluting stents (DES) and advances in adjunctive pharmacotherapy, but latest evidence is rare. The aim of this study is to evaluate the association between baseline platelet count (PC) and severe adverse outcomes following percutaneous coronary intervention (PCI) in current real-world practice both at short-term and long-term follow-up by analyzing data from the Beijing Heart and Metabolism Survey (BHMS).

2. Methods {#s2}
==========

2.1. Study design and patient population {#s2a}
----------------------------------------

BHMS is an investigator-initiated, multicenter cohort study conducted at five tertiary medical centers. The PC obtained at baseline, using a Coulter Counter method, was considered. From April 2004 to October 2010, a total of 21,620 consecutive patients receiving PCI were recruited. And only those implanted with DES were considered eligible for the study. To enhance homogeneity and ensure examination of a representative cohort in the context of contemporary treatment regimens, 843 (3.9%) patients receiving plain old balloon angioplasty without stent implantation and 1738 (8.0%) patients who underwent BMS implantation were excluded. Two hundred and eleven (1.0%) patients without completed baseline data and 40 (0.2%) with a terminal illness were also excluded. Thus a total of 18,788 patients constituted the cohort. Patients in our cohort were categorized as having low (\< 150 × 1000/µL), normal (150--300 × 1000/µL), and high (≥ 300 × 1000/µL) baseline PC. In the overall cohort, the average length of in-hospital stay was 8 ± 6 days and the mean length of follow-up was about 2 years (25 ± 17 months). [Figure 1](#jgc-15-05-346-g001){ref-type="fig"} shows the study design and flow chart. The study protocol was reviewed and approved by the Ethics Committee of each participating institution.

![The study flow chart.\
PCI: percutaneous coronary intervention; PC: platelet count; AHA/ACC: American Heart Association/American College of Cardiology; DES: drug eluting stent; BMS: bare metal stent.](jgc-15-05-346-g001){#jgc-15-05-346-g001}

2.2. Clinical endpoints {#s2b}
-----------------------

The primary endpoints were in-hospital and follow-up all-cause mortality. The secondary endpoint was major bleeding requiring a blood transfusion. The tertiary endpoints included length of stay before PCI, length of stay after PCI, length of in-hospital stay, and the total hospitalization expenses.

2.3. Statistical analysis {#s2c}
-------------------------

Statistical analysis was performed using Statistical Package for Social Sciences (SPSS). All categorical variables were expressed as percentages and compared with Pearson chi-square test or Fisher exact test; continuous variables were expressed as median (interquartile range) and nonparametric tests were used (Kruskal-Wallis test for \> 2 groups). Multivariate analyses with Cox proportional hazards methods derived the independent predictors of adverse events. Variables were selected for submission to the model if the univariate *P* value was \< 0.25 or the variable was of known clinical significance but failed to meet the critical α level for inclusion.[@b7]--[@b15]

3. Results {#s3}
==========

3.1. Baseline demographic and clinical characteristics {#s3a}
------------------------------------------------------

As an overall cohort, the mean ± SD age was 60 ± 11 years with the median age of 60 (52--68) years. Male patients (*n* = 13,922) account for 74.1% of the cohort. There were 5384 (28.7%), 11,425 (60.8%), 2832 (15.1%), and 2915 (15.5%) patients had a history of diabetes mellitus (DM), hypertension, hyperlipidemia and prior myocardial infaction (MI), respectively. A total of 13,283 patients had the myocardial dysfunction with different New York Heart Association (NYHA) functional classes, among which class II, III and IV accounted for 54.6%, 12.8% and 3.4%, respectively. The prevalences of stable coronary artery disease (SCAD), unstable angina pectoris (UAP) and acute myocardial infarction (AMI) were 23.2%, 48.5% and 28.3%, respectively.

3.2. Distribution of baseline PC {#s3b}
--------------------------------

The distribution of baseline PC was a skewed distribution with a median value of 2 × 1000/µL (165--240 × 1000/µL) and a mean value of (206 ± 60) × 1000/µL ([Figure 2A](#jgc-15-05-346-g002){ref-type="fig"}). A majority of the baseline PC (14,633, 77.9%) were normally distributing in the range of 150--300 × 1000/µL ([figure 2B](#jgc-15-05-346-g002){ref-type="fig"}). In addition, there were 2884 (15.4%), 1271 (6.8%) patients had their baseline PC \< 150 × 1000/µL, and ≥ 300 × 1000/µL, respectively. Only 11 patients had their baseline PC lower than 50 × 1000/µL with the minimum value of 13 × 1000/µL ([Figure 2C](#jgc-15-05-346-g002){ref-type="fig"}). And 4 patients in the high group had their baseline PC higher than 600 × 1000/µL with the maximum value of 664 × 1000/µL ([Figure 2D](#jgc-15-05-346-g002){ref-type="fig"}).

![The distribution of baseline platelet count.\
(A): The distribution of baseline platelet count in the overall cohort; (B): the distribution of baseline platelet count in the normal group; (C): the distribution of baseline platelet count in the low group; (D): the distribution of baseline platelet count in the high group.](jgc-15-05-346-g002){#jgc-15-05-346-g002}

3.3. Comparison of baseline characteristics among groups {#s3c}
--------------------------------------------------------

As detailed in [Table 1](#jgc-15-05-346-t01){ref-type="table"}, among the 3 groups there were major differences in baseline clinical characteristics, which in the low group were almost the opposite of the high group. From an angiographic and procedural viewpoint ([Table 2](#jgc-15-05-346-t02){ref-type="table"}), patients with lower baseline PC were more likely to have left main (LM) disease and left main multi-vessel disease (LMMVD). They were treated somewhat more frequently with single stent with shorter length and larger diameter. In addition, transradial approach PCI was more likely preferred in the low group. Compared with the normal group, patients in the high group were also more likely to have LM disease and were treated more frequently with single stent with relatively shorter length and larger diameter.

###### Baseline clinical characteristics.

  Characteristics                    Low (*n* = 2884)    Normal (*n* = 14633)   High (*n* = 1271)   *P* value
  --------------------------------- ------------------- ---------------------- ------------------- -----------
  Clinical variables                                                                               
   Age, yrs                             64 (55, 71)          59 (52, 68)           57 (49, 66)      \< 0.001
   Age ≥ 75, yrs                        351 (12.2%)          1115 (7.6%)            75 (5.9%)       \< 0.001
   Female                               519 (18.0%)          3906 (26.7%)          441 (34.7%)      \< 0.001
   Diabetes                             901 (31.2%)          4146 (28.3%)          337 (26.5%)        0.001
   Hypertension                        1682 (58.3%)          8974 (61.3%)          769 (60.5%)        0.010
   Hyperlipidemia                       344 (11.9%)          2284 (15.6%)          204 (16.1%)      \< 0.001
   Prior myocardial infarction          374 (13.0%)          2328 (15.9%)          213 (16.8%)      \< 0.001
   Diagnosis                                                                                       
    SCAD                                706 (24.5%)          3389 (23.2%)          273 (21.5%)     
    UAP                                1377 (47.7%)          7207 (49.3%)          521 (41.0%)      \< 0.001
    AMI                                 801 (27.8%)          4037 (27.6%)          477 (37.5%)     
   NYHA functional classification                                                                  
    Class 1                             798 (27.7%)          4287 (29.3%)          421 (33.1%)     
    Class 2                            1551 (53.8%)          8092 (55.3%)          624 (49.1%)     
    Class 3                             409 (14.2%)          1800 (12.3%)          179 (14.1%)        0.073
    Class 4                             126 (4.4%)            454 (3.1%)            47 (3.7%)      
  Laboratory variables                                                                             
   Creatinine, umol/L                80.8 (69.0, 94.0)    77.0 (66.0, 90.1)     73.1 (61.1, 85.4)   \< 0.001
   FPG, mmol/L                        6.0 (5.1, 7.9)        5.9 (5.1, 7.4)       5.8 (5.0, 7.2)     \< 0.001
   LDL-C, mmol/L                      2.6 (2.0, 3.2)        2.8 (2.3, 3.5)       3.0 (2.4, 3.7)     \< 0.001
   HDL-C, mmol/L                      0.9 (0.8, 1.1)        0.9 (0.8, 1.1)       0.9 (0.8, 1.1)     \< 0.001
   K^+^, mmol/L                       4.0 (3.8, 4.3)        4.1 (3.9, 4.4)       4.3 (4.0, 4.5)     \< 0.001
   LVEDD, mm                            49 (46, 53)          48 (45, 52)           49 (45, 53)      \< 0.001
   LVEF, %                              62 (54, 68)          62 (55, 68)           62 (55, 68)        0.001

Data were presented as median (interquartile range) for quantitative variables or as *n* (%) for qualitative variables. AMI: acute myocardial infarction; FPG: fasting plasma, glucose; HDL-C: high-density lipoprotein cholesterol; K^+^: potassium ion; LDL-C: low-density lipoprotein cholesterol; LVEDD: left ventricular end diastolic dimension; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; SCAD: stable coronary artery disease; UAP: unstable angina pectoris.

###### Angiographic and procedural characteristics.

  Characteristics                                        Low (*n* = 2884)   Normal (*n* = 14633)   High (*n* = 1271)   *P* Value
  ----------------------------------------------------- ------------------ ---------------------- ------------------- -----------
  Angiographic stenosis location                                                                                      
   LM                                                       170 (5.9%)           745 (5.1%)            81 (6.4%)         0.045
   LAD                                                     2196 (76.1%)        1,1035 (75.4%)         974 (76.6%)        0.477
   LCX                                                     1455 (50.5%)         7163 (49.0%)          591 (46.5%)        0.060
   RCA                                                     1569 (54.4%)         7661 (52.4%)          662 (52.1%)        0.120
  LM or multivessel disease                                1717 (59.5%)         8369 (57.2%)          713 (56.1%)        0.039
  Number of stents implanted                                 1 (1, 2)             1 (1, 2)              1 (1,2)        \< 0.001
  Single stent implanted                                   1866 (64.7%)         8531 (58.3%)          770 (60.6%)      \< 0.001
  Stent diameter, mm                                     3.0 (2.75, 3.5)       3.0 (2.5, 3.5)       3.0 (2.5, 3.5)       0.003
  Stent diameter \< 3.0 mm                                 1058 (36.7%)         6204 (42.4%)          520 (40.9%)      \< 0.001
  Stent length, mm                                         21 (18, 28)          24 (18, 29)           24 (18, 28)      \< 0.001
  Intraoperative GP IIb/IIIa inhibitor administration      326 (11.3%)          2283 (15.6%)          244 (19.2%)      \< 0.001
  Transradial approach                                     1568 (54.4%)         6848 (46.8%)          599 (47.1%)      \< 0.001

Results are expressed as median (interquartile range) for quantitative variables or as *n* (%) for qualitative variables. LAD; left anterior descending; LCX: left circumflex; LM: left main; RCA: right coronary artery.

With respect to medications used in hospital and upon discharge ([Table 3](#jgc-15-05-346-t03){ref-type="table"}), there were no significant differences regarding the use of clopidogrel among the 3 groups, whereas maintenance dose and loading dose of aspirin tended to be lower in the low group. The use of proton pump inhibitor (PPI) was more frequent in the patients with lower baseline PC than the others.

###### Medications used in hospital and upon discharge.

  Variable                         Low (*n* = 2884)   Normal (*n* = 14633)   High (*n* = 1271)   *P* value
  ------------------------------- ------------------ ---------------------- ------------------- -----------
  Aspirin                                                                                       
   Loading therapy                                                                              
    Loading dose ≥ 300 mg/d          2466 (85.5%)        12862 (87.9%)         1098 (86.4%)     
    Loading dose \< 300 mg/d          176 (6.1%)           849 (5.8%)            75 (5.9%)         0.058
    No loading dose                   242 (8.4%)           922 (6.3%)            98 (7.7%)      
   Maintenance therapy                                                                          
    Maintenance dose ≥ 81 mg/d       2527 (87.6%)        12956 (88.5%)         1101 (86.6%)     
    Maintenance dose \< 81 mg/d       218 (7.6%)           849 (5.8%)            79 (6.2%)         0.010
    No maintenance dose               139 (4.8%)           828 (5.7%)            91 (7.2%)      
  Clopidogrel                                                                                   
   Loading therapy                                                                              
    Loading dose ≥ 300 mg/d          2662 (92.3%)        13477 (92.1%)         1174 (92.4%)     
    Loading dose \< 300 mg/d          173 (6.0%)           922 (6.3%)            75 (5.9%)         0.162
    No loading dose                   49 (1.7%)            234 (1.6%)            22 (1.7%)      
   Maintenance therapy                                                                          
    Maintenance dose ≥ 75 mg/d       2788 (96.7%)        14169 (96.8%)         1229 (96.7%)     
    Maintenance dose \< 75 mg/d       61 (2.1%)            293 (2.0%)            26 (2.0%)         0.946
    No maintenance dose               35 (1.2%)            171 (1.2%)            16 (1.3%)      
  LMWH                               2168 (75.2%)        11116 (76.0%)          925 (72.8%)        0.033
  PPI                                1358 (47.1%)         6266 (42.8%)          524 (41.2%)      \< 0.001
  Statin                             2628 (91.1%)        13338 (91.2%)         1133 (89.1%)        0.055
  ACEI                               1460 (50.6%)         7435 (50.8%)          663 (52.2%)        0.625
  ARB                                506 (17.5%)          2567 (17.5%)          211 (16.6%)        0.695
  CCB                                744 (25.8%)          4272 (29.2%)          368 (29.0%)        0.001
  β-blocker                          1960 (68.0%)        10141 (69.3%)          832 (65.5%)        0.010

Data were presented as n (%) for qualitative variables. ACEI: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blockers; CCB: calcium channel blockers; LMWH: low molecular weight heparins; PPI: proton pump inhibitors.

3.4. Association between baseline PC and clinical outcomes {#s3d}
----------------------------------------------------------

### 3.4.1. Primary endpoints {#s3d1}

In the overall cohort, 77 patients (0.4%) died in the hospital, and 120 patients (0.6%) died during the long-term follow-up (median 23.8 months). Compared with the normal group, both the low and high groups had the similar in-hospital and follow-up all-cause mortality ([Table 4](#jgc-15-05-346-t04){ref-type="table"}). In-hospital mortality rates for patients in the low, normal, and high group were 0.6%, 0.4%, and 0.4%, respectively; *P* = 0.259; and follow-up mortality rates for patients in the low, normal, and high group were 0.9%, 0.6%, and 0.7%, respectively; *P* = 0.079. After multivariable adjustment, patients with lower or higher baseline PC tended to have similar risks for both in-hospital and follow-up mortality compared with the normal group. As indicated in [Table 5](#jgc-15-05-346-t05){ref-type="table"}, hazard ratios (HRs) and 95% confidence intervals (CIs) of in-hospital death for the low and high group were 0.843 (95% CI: 0.412--1.723; *P* = 0.639) and 0.668 (95% CI: 0.236--1.890; *P* = 0.447), respectively; and the HRs of follow-up death for the low and high group were 1.204 (95% CI: 0.708--2.049; *P* = 0.493) and 0.942 (95% CI: 0.407--2.181; *P* = 0.889), respectively. Further subgroup analyses failed to demonstrate independent prognostic value of baseline PC in specific population groups except patients underwent transfemoral PCI ([Figure 3](#jgc-15-05-346-g003){ref-type="fig"}). Kaplan--Meier curves of in-hospital ([Figure 4A](#jgc-15-05-346-g004){ref-type="fig"}) and follow-up mortality ([Figure 4B](#jgc-15-05-346-g004){ref-type="fig"}) were presented in [Figure 4](#jgc-15-05-346-g004){ref-type="fig"}. The cumulative survival rates in patients with low or high baseline PC continued to be similar to that in normal group (*P* = 0.548 and 0.082, respectively).

###### Clinical outcomes at follow-ups.

  Variable                                         Low (*n* = 2884)   Normal (*n* = 14,633)   High (*n* = 1271)   *P* value
  ----------------------------------------------- ------------------ ----------------------- ------------------- -----------
  Primary endpoints                                                                                              
   In-hospital mortality                              17 (0.6%)             55 (0.4%)             5 (0.4%)          0.259
   Follow-up mortality                                27 (0.9%)             84 (0.6%)             9 (0.7%)          0.079
  Secondary endpoints                                                                                            
   Major bleeding requiring a blood transfusion       13 (0.5%)             41 (0.3%)             4 (0.3%)          0.320

###### Independent predictors of in-hospital and long-term mortality.

  Variable                                               In-hospital mortality   Two-year mortality                                        
  ----------------------------------------------------- ----------------------- -------------------- ---------- ----------- -------------- ----------
  Age ≥ 75 yrs                                                   2.277              1.264--4.102       0.006       3.103     1.908--5.044   \< 0.001
  Female                                                         2.240              1.321--3.800       0.003       1.577     1.002--2.480    0.049
  Hypertension                                                   0.825              0.484--1.404       0.478       0.792     0.514--1.219    0.289
  AMI                                                            3.024              1.736--5.267      \< 0.001     2.296     1.473--3.581   \< 0.001
  Baseline PC                                                                                                                              
   Low                                                           0.843              0.412--1.723       0.639       1.204     0.708--2.049    0.493
   Normal                                                      1.0 (Ref)                ---                      1.0 (Ref)       ---       
   High                                                          0.668              0.236--1.890       0.447       0.942     0.407--2.181    0.889
  Creatinine, umol/L                                             1.004              1.001--1.007       0.017       1.004     1.002--1.007    0.001
  FPG, mmol/L                                                    0.958              0.869--1.057       0.396       1.062     0.997--1.131    0.061
  LDL-C, mmol/L                                                  1.164              0.889--1.522       0.269       0.972     0.771--1.224    0.807
  LVEF, %                                                        0.975              0.954--0.996       0.021       0.973     0.955--0.991    0.003
  LM or multivessel disease                                      1.830              0.980--3.419       0.058       1.655     1.031--2.655    0.037
  Single stent implanted                                         0.854              0.396--1.460       0.183       0.924     0.650--0.998    0.035
  Stent diameter \< 3.0 mm                                       1.238              0.474--1.981       0.252       1.195     0.623--1.711    0.142
  Stent length, mm                                               1.009              0.874--1.673       0.470       1.016     0.883--1.910    0.236
  Intraoperative GP IIb/IIIa inhibitor administration            0.910             0.671--1. 158       0.086       0.974     0.683--2.265    0.391
  Transradial approach                                           0.782              0.445--0.974       0.006       0.873     0.516--0.983    0.035
  Aspirin                                                        0.464              0.208--1.035       0.061       0.601     0.283--1.274    0.184
  Clopidogrel                                                    0.181              0.052--0.630       0.007       0.221     0.069--0.707    0.011

AMI: acute myocardial infarction; CI: confidence interval; FPG: fasting plasma, glucose; GP: glycoprotein; HR: hazard ratio; LDL-C: low-density lipoprotein cholesterol; LM: left main; LVEF: left ventricular ejection fraction; PC: platelet count.

![Subgroup analyses of the prognostic value of baseline platelet count.\
(A): Relationship between baseline platelet count and in-hospital mortality in subgroups; (B): relationship between baseline platelet count and follow-up mortality in subgroups. AMI: acute myocardial infarction; CI: confidence intervals; HR: hazard ratio; SCAD: stable coronary artery disease; UAP: unstable angina pectoris.](jgc-15-05-346-g003){#jgc-15-05-346-g003}

![Kaplan--Meier curves of in-hospital and follow-up mortality.\
(A): Kaplan--Meier curves of in-hospital mortality; (B): Kaplan--Meier curves of follow-up mortality.](jgc-15-05-346-g004){#jgc-15-05-346-g004}

### 3.4.2. Secondary endpoint {#s3d2}

There was also no significant difference in the incidence of hemorrhage among groups (major bleeding requiring a blood transfusion in the low, normal, and high group were 0.5%, 0.3%, and 0.3%, respectively; *P* = 0.320). After multivariable adjustment, low (HR: 1.978; 95% CI: 0.975--3.818; *P* = 0.052) or high baseline PC (HR: 1.264; 95% CI: 0.443--3.601; *P* = 0.662) did not significantly increase the risk of major bleeding ([Table 6](#jgc-15-05-346-t06){ref-type="table"}).

###### Independent predictors of major bleeding requiring a blood transfusion.

  Variable                                                  OR          95% CI      *P* Value
  ----------------------------------------------------- ----------- -------------- -----------
  Age ≥ 75 yrs                                             0.862     0.306--2.430     0.779
  Female                                                   1.924     1.028--3.600     0.041
  Hypertension                                             0.801     0.45 --1.423     0.449
  History of stroke                                        1.409     0.430--4.616     0.571
  AMI                                                      2.228     1.234--4.024     0.008
  Baseline PC                                                                      
   Low                                                     1.978     0.975--3.818     0.052
   Normal                                                1.0 (Ref)       ---       
   High                                                    1.264     0.443--3.601     0.662
  Hematocrit, %                                            0.958     0.932--0.983     0.001
  Creatinine, umol/L                                       1.006     1.002--1.009     0.001
  FPG, mmol/L                                              1.009     0.914--1.113     0.862
  LDL-C, mmol/L                                            0.994     0.732--1.350     0.968
  LVEF, %                                                  0.968     0.944--0.993     0.013
  LM or multivessel disease                                1.223     0.680--2.199     0.502
  Intraoperative GP IIb/IIIa inhibitor administration      1.216     0.787--3.458     0.435
  Transradial approach                                     0.762     0.391--0.960     0.030
  Aspirin                                                  1.669     0.826--2.570     0.558
  Clopidogrel                                              1.125     1.029--1.532     0.005
  PPI                                                      0.893     0.455--0.996     0.062

AMI: acute myocardial infarction; CI: confidence interval; FPG: fasting plasma, glucose; GP: glycoprotein; LDL-C: low-density lipoprotein cholesterol; LM: left main; LVEF: left ventricular ejection fraction; OR: odds ratios; PC: platelet count; PPI: proton pump inhibitors.

### 3.4.3. Tertiary endpoints {#s3d3}

Although none of the tertiary endpoints were clinical adverse events, any of them could indirectly reflect the general incidence of severe adverse events. As indicated in [Figure 5A](#jgc-15-05-346-g005){ref-type="fig"}, there was no significant difference in the total hospitalization expenses among groups (*P* = 0.342). There were statistically significant differences in the length of in-hospital stay (median value in three groups were all 7 days, *P* \< 0.001) ([Figure 5B](#jgc-15-05-346-g005){ref-type="fig"}), the length of stay before PCI (median value in three groups were all 2 days, *P* = 0.047) ([Figure 5C](#jgc-15-05-346-g005){ref-type="fig"}), the length of stay after PCI (median value in 3 groups were all 4 days, *P* \< 0.001) ([Figure 5D](#jgc-15-05-346-g005){ref-type="fig"}), but the statistical differences did not translate into clinical importance.

![Comparisons of the tertiary endpoints among groups with different baseline platelet count.\
(A): Comparisons of the total hospitalization expenses among groups; (B): comparisons of the length of in-hospital stay among groups; (C): comparisons of the length of stay before PCI among groups; (D): comparisons of the length of stay after PCI among groups. CNY: Chinese Yuan; PCI: percutaneous coronary intervention.](jgc-15-05-346-g005){#jgc-15-05-346-g005}

4. Discussion {#s4}
=============

The PCI technique and the adjunctive pharmacotherapy have made great progress in the following several decades.[@b16] However, thrombosis and hemorrhage have always been the the major cause of morbidity and mortality in patients underwent PCI.[@b1],[@b2] Therefore, patients with impaired quantity and quality of platelets were often excluded from prospective randomized controlled trials because of the potential increased risks of thrombosis and hemorrhage following PCI. Few pooled post-hoc analyses[@b7]--[@b15] and cohort studies[@b13]--[@b15] drew inconsistent conclusions based on data mostly from thrombolysis or BMS era.

Gibson, *et al.*[@b12] demonstrated that in patients with ST-elevation myocardial infarction (STEMI) who were treated with aspirin, high baseline PC was independently associated with increased rates of reinfarction at 30-day follow-up. However, clopidogrel therapy abolished this increase in the risk of reinfarction as PC increased. Iijima, *et al.*[@b7] argued that in patients underwent PCI after pre-treatment with 600 mg clopidogrel, high baseline PC was still independently associated with 30-day mortality. Others[@b9]--[@b11] agreed with that, high baseline PC was independently associated with an increased risk of adverse events following PCI. Whereas there was one more post-hoc analysis[@b8] revealing that low baseline PC in STEMI patients underwent PCI was strongly associated with 30-day adverse events but not with any 2-year adverse events. Similarly, a cohort study[@b15] showed that in-hospital death rate was higher in patients with low baseline PC due to an increased mortality in AMI patients underwent urgent but not elective PCI. In another cohort study,[@b14] baseline PC was not an independent predictor of 30-day mortality in AMI patients after adjustment of confounders. Interestingly, a U-shaped association between baseline PC and long-term outcomes was also proposed.[@b13] Wu, *et al.*[@b17] demonstrated a significant association between baseline PC and clinical outcomes by meta-analysis of the above eight studies.[@b9]--[@b13],[@b15]--[@b17] They confirmed a U-shaped relationship between baseline PC and the risk of mortality and adverse events. At 1-month follow-up, compared with the low PC group (\< 150 × 1000/µL), the pooled relative risks of mortality and adverse events were 1.78 and 1.63 for the high PC group (\> 350 × 1000/µL). At long-term follow-up, the pooled relative risks of mortality and adverse events were 1.48 and 1.28, respectively, for the high PC group.

However, the above studies have many limitations. Firstly, most of the patient population were AMI[@b9]--[@b12],[@b14],[@b16] or high-risk patients with acute coronary syndrome (ACS).[@b13],[@b17] Even in the remainder one study,[@b15] the elective PCI accounted for less than 50%. Accordingly, conclusions drawn from the above studies could not be applicable to all CAD patients. Secondly, the sample sizes of such studies did not provide sufficient statistical power to detect low incidences of events in all prespecified groups according to clinical significance. Although equal interval classification[@b10],[@b12],[@b17] could increase statistical power, it might reduce the clinical significance of the cut-off points. Thirdly, not all patients in the above studies underwent PCI.[@b9],[@b11]--[@b13],[@b16],[@b17] Lastly, and most important of all, some latest advances recommended by guidelines[@b18]--[@b20] were not reflected in the above studies, including DAPT, transradial approach for PCI, and PPI, etc.

Different from previous studies, we found that there were no significant differences among patients with different baseline PC in severe adverse outcomes, including in-hospital mortality, long-term follow-up mortality, and major bleeding requiring a blood transfusion. Although the exact mechanism is not fully understood, several factors with well-established benefits may be involved in the changing pattern between baseline PC and outcomes, including increased use of clopidogrel added to aspirin,[@b21]--[@b24] transradial approach PCI,[@b25]--[@b27] PPI,[@b28],[@b29] and optimization of stent implantation.[@b30],[@b31]

5. Conclusions {#s5}
==============

There is no significant association between baseline PC and severe adverse outcomes following PCI in current real-world practice.
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